Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News


VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

July 30, 2020
Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Outbreak Control Agent Against COVID-19
June 24, 2020
Appili Therapeutics Announces FY 2020 Annual and Financial Results
June 15, 2020
Appili Therapeutics Commences Trading on the OTCQX Marketplace